Cytek Biosciences (CTKB) Change in Accured Expenses (2020 - 2026)

Cytek Biosciences' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$3.9 million for Q1 2026.

• Quarterly Change in Accured Expenses fell 83.4% year-over-year to -$3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 32.51% YoY) and the FY2025 annual result came in at $4.0 million, up 585.92% from the prior year.
• Change in Accured Expenses was -$3.9 million for Q1 2026 at Cytek Biosciences, down from $4.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.6 million in Q3 2024 and bottomed at -$4.8 million in Q2 2024.
• A 5-year average of $438941.2 and a median of $335000.0 in 2023 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 2368.91% in 2024, while the deepest fall reached 360.86% in 2024.
• Cytek Biosciences' Change in Accured Expenses stood at $4.6 million in 2022, then tumbled by 97.44% to $119000.0 in 2023, then soared by 2368.91% to $2.9 million in 2024, then jumped by 60.28% to $4.7 million in 2025, then sank by 182.61% to -$3.9 million in 2026.
• Business Quant data shows CTKB's Change in Accured Expenses at -$3.9 million in Q1 2026, $4.7 million in Q4 2025, and -$1.4 million in Q3 2025.